A citation-based method for searching scientific literature

Sandro Pignata, Sabrina Chiara Cecere. Future Oncol 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Bradley J Monk, Thomas J Herzog, Stanley B Kaye, Carolyn N Krasner, Jan B Vermorken, Franco M Muggia, Eric Pujade-Lauraine, Alla S Lisyanskaya, Anatoly N Makhson, Janusz Rolski,[...]. J Clin Oncol 2010
267
100

Treatment of recurrent ovarian cancer.
S Pignata, S C Cecere, A Du Bois, P Harter, F Heitz. Ann Oncol 2017
77
100

Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Rosemary Lord, Jyoti Rauniyar, Tamsin Morris, Orlaith Condon, Rachel Jones, Rowan Miller, Marcia Hall, Fiona Lofts, Rosalind M Glasspool, Emma Hudson. Int J Gynecol Cancer 2020
2
100

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
Ingo B Runnebaum, Dietmar Reichert, Uta Ringsdorf, Markus Kuther, Tobias Hesse, Jalid Sehouli, Pauline Wimberger. J Cancer Res Clin Oncol 2018
2
100

GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
FrÉdÉric Selle, Pierre-Etienne Heudel, Anne-Claire Hardy-Bessard, Astrid Pozet, Jerome Meunier, Laurence Gladieff, Jean-Pierre Lotz, Magali Provansal, Paule Augereau, Dominique Berton,[...]. Anticancer Res 2020
2
100

Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?
Federica Tomao, Maurizio D'Incalci, Elena Biagioli, Fedro A Peccatori, Nicoletta Colombo. Cancer 2017
19
100


Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience.
Claudia Marchetti, Angela Musella, Alessia Romito, Laura Vertechy, Innocenza Palaia, Violante Di Donato, Serena Boccia, Francesca De Felice, Marco Monti, Ludovico Muzii,[...]. Oncology 2017
1
100

Unique features of trabectedin mechanism of action.
Annette K Larsen, Carlos M Galmarini, Maurizio D'Incalci. Cancer Chemother Pharmacol 2016
85
100

ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
N Colombo, C Sessa, A du Bois, J Ledermann, W G McCluggage, I McNeish, P Morice, S Pignata, I Ray-Coquard, I Vergote,[...]. Ann Oncol 2019
207
100

Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.
Ronald D Alvarez, Ursula A Matulonis, Thomas J Herzog, Robert L Coleman, Bradley J Monk, Maurie Markman. Gynecol Oncol 2016
21
100

Progress in the management of gynecologic cancer: consensus summary statement.
Stephen A Cannistra, Robert C Bast, Jonathan S Berek, Michael A Bookman, Christopher P Crum, Paul D DePriest, Judy E Garber, Wui-Jin Koh, Maurie Markman, William P McGuire,[...]. J Clin Oncol 2003
43
100

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
Maurie Markman, Jonathan Markman, Kenneth Webster, Kristine Zanotti, Barbara Kulp, Gertrude Peterson, Jerome Belinson. J Clin Oncol 2004
161
100


Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.
Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero, Jose Antonio Lopez-Guerrero, Nicoletta Colombo. Cancer Treat Rev 2014
44
100


Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.
Maria Ornella Nicoletto, Alessandra Baldoni, Alessandra Casarin, Giovanni Randon, Margherita Nardin, Zora Baretta, Pilar Lardelli, Antonio Nieto, Vicente Alfaro, Claudia Rigamonti,[...]. Tumori 2015
8
100

Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.
Gabriella Ferrandina, Vanda Salutari, Bruno Vincenzi, Marco Marinaccio, Emanuele Naglieri, Vera Loizzi, Silvia Carpano, Giulia Amadio, Giuseppe Tonini, Giovanni Scambia,[...]. Gynecol Oncol 2013
15
100

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Val Gebski, Mark Heywood, Paul A Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero,[...]. J Clin Oncol 2010
342
100

Wise Management of Ovarian Cancer: On the Cutting Edge.
Stergios Boussios, Christos Mikropoulos, Eleftherios Samartzis, Peeter Karihtala, Michele Moschetta, Matin Sheriff, Afroditi Karathanasi, Agne Sadauskaite, Elie Rassy, Nicholas Pavlidis. J Pers Med 2020
34
100

1
100

Real-world data: towards achieving the achievable in cancer care.
Christopher M Booth, Safiya Karim, William J Mackillop. Nat Rev Clin Oncol 2019
70
100

How to approach patients in relapse.
E Pujade-Lauraine. Ann Oncol 2012
19
100

Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
Nicoletta Colombo, Anne-Claire Hardy-Bessard, Gabriella Ferrandina, Christian Marth, Ignacio Romero. Expert Rev Anticancer Ther 2016
3
100

Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
Stergios Boussios, Peeter Karihtala, Michele Moschetta, Charlotte Abson, Afroditi Karathanasi, Nikolaos Zakynthinakis-Kyriakou, Jake Edward Ryan, Matin Sheriff, Elie Rassy, Nicholas Pavlidis. Invest New Drugs 2020
31
100

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
M K Wilson, E Pujade-Lauraine, D Aoki, M R Mirza, D Lorusso, A M Oza, A du Bois, I Vergote, A Reuss, M Bacon,[...]. Ann Oncol 2017
107
100

Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
Isabelle Ray-Coquard, Mansoor Raza Mirza, Sandro Pignata, Axel Walther, Ignacio Romero, Andreas du Bois. Cancer Treat Rev 2020
6
100


Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience.
Guillaume Moriceau, Romain Rivoirard, Benoîte Méry, Alexis Vallard, Cécile Pacaut, Jane-Chloé Trone, Sophie Espenel, Claire Bosacki, Jean-Philippe Jacquin, Nicolas Magné. Chemotherapy 2016
7
100

Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Ignacio Romero, Pedro Mallol, Ana Santaballa, Jose M Del Campo, Marta Mori, Santiago González-Santiago, Antonio Casado, David Vicente, Eugenia Ortega, Ana Herrero,[...]. Anticancer Drugs 2019
5
100

Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.
Antonio Casado, Hector R Callata, Aranzazu Manzano, Gloria Marquina, Teresa Alonso, Pablo Gajate, Miguel Sotelo, Santiago Cabezas, Cristina Fernández, Eduardo Díaz-Rubio. Future Oncol 2019
4
100

Real-world Data for Clinical Evidence Generation in Oncology.
Sean Khozin, Gideon M Blumenthal, Richard Pazdur. J Natl Cancer Inst 2017
122
100

Real-World Evidence - What Is It and What Can It Tell Us?
Rachel E Sherman, Steven A Anderson, Gerald J Dal Pan, Gerry W Gray, Thomas Gross, Nina L Hunter, Lisa LaVange, Danica Marinac-Dabic, Peter W Marks, Melissa A Robb,[...]. N Engl J Med 2016
777
100



Trabectedin in Ovarian Cancer: is it now a Standard of Care?
J Ventriglia, I Paciolla, S C Cecere, C Pisano, M Di Napoli, L Arenare, S V Setola, N S Losito, D Califano, M Orditura,[...]. Clin Oncol (R Coll Radiol) 2018
10
100

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.
B Colmegna, S Uboldi, R Frapolli, S A Licandro, N Panini, C M Galmarini, Nadia Badri, V J Spanswick, J P Bingham, Konstantinos Kiakos,[...]. Br J Cancer 2015
30
100

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Bradley J Monk, Thomas J Herzog, Stanley B Kaye, Carolyn N Krasner, Jan B Vermorken, Franco M Muggia, Eric Pujade-Lauraine, Youn C Park, Trilok V Parekh, Andres M Poveda. Eur J Cancer 2012
60
100

When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
Jessica M Franklin, Sebastian Schneeweiss. Clin Pharmacol Ther 2017
95
100

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer.
Eva María Guerra Alía, Cayetano Sempere Ortega, Alfonso Cortés Salgado, Concepción Sanchez Martínez, Julio Galindo Álvarez, Belén Pérez Miez. Case Rep Oncol 2019
1
100


Recurrent ovarian cancer: when and how to treat.
Marcia Hall, Gordon Rustin. Curr Oncol Rep 2011
19
100

A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Sandro Pignata, Giovanni Scambia, Alessandro Villanucci, Emanuele Naglieri, Mikel Arruti Ibarbia, Federica Brusa, Hugues Bourgeois, Roberto Sorio, Antonio Casado, Dietmar Reichert,[...]. Oncologist 2021
3
100

Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade.
Willi Oberaigner, Pamela Minicozzi, Magdalena Bielska-Lasota, Claudia Allemani, Roberta de Angelis, Lucia Mangone, Milena Sant. Acta Oncol 2012
67
100

Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
Bradley J Monk, Heather Dalton, Ivor Benjamin, Adnan Tanović. Curr Pharm Des 2012
14
100

Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
Jean-Philippe Adam, Feriel Boumedien, Nathalie Letarte, Diane Provencher. Gynecol Oncol 2017
3
100


A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Bradley J Monk, Thomas J Herzog, George Wang, Spyros Triantos, Scott Maul, Roland Knoblauch, Tracy McGowan, Waleed S W Shalaby, Robert L Coleman. Gynecol Oncol 2020
10
100



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.